Cocrystal Pharma, Inc. (COCP)
$1.06-0.93%Close
SELLCRISIS · day 4
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $11M
- Beta
- 1.48
- P/E (TTM)
- -1.44
- Short % float
- 2.59%
- Days to cover
- 3.2
- SI change
- -45.7%
- 1W
- -4.50%
- 1M
- -14.52%
- vs SPY 1W
- -4.93%
- vs SPY 1M
- -16.58%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 1
- GROWTH
- 9
- GARP
- 1
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-124.5%
REV YoY-
ROE-207.5%
EPS YoY-
ROA-213.8%
GROSS206
OP-3064
NET-3012
[VALUATION]
P/E TTM-1.44
P/E FWD-
SECTOR PE20.54
INDUSTRY PE14.03
P/B14.66
P/FCF-
EV/EBITDA-1.52
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E128.45
ALTMAN Z-
CURR RATIO1.24
ND/EBITDA-
BETA1.48
Company news
FAQ
- What is LOPJLB’s current signal on COCP?
- LOPJLB’s latest quantitative signal on Cocrystal Pharma, Inc. (COCP) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is COCP in?
- Cocrystal Pharma, Inc. (COCP) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Cocrystal Pharma, Inc. (COCP) do?
- Cocrystal Pharma, Inc. (COCP) is a biotechnology firm dedicated to researching and advancing antiviral treatments for severe and/or persistent viral illnesses. The company leverages structure-based technologies to create new antiviral medications, primarily focusing on infections caused by the hepatitis C virus (HCV), influenza, coronaviruses, and noroviruses. Its current pipeline includes CC-3…